COGT Shorts Retreat as the Stock Bounces Into November Earnings

Cogent Biosciences has snapped back 11% in a week, and the bears who spent the summer building their position are now quietly retreating ahead of a November 2 earnings date that also carries FDA pipeline catalysts.

The shift in short positioning is the clearest change since the last note. Three days ago this column flagged shorts at their most aggressive in the dataset, with short interest having climbed from below 7% of the free float in mid-June to above 12% by early October. That peak is now fading. Short interest has dropped 4.2% over the past week to 12.76% of the free float, equivalent to roughly 19.4 million shares. The direction of travel has reversed, and with the stock up from $29.52 to $31.24 in two trading days, some of that retreat looks like covering under pressure. Days to cover remain elevated at 8.1 per the most recent FINRA settlement data, so the position is not small. Still, the borrow market offers no signal of distress: cost to borrow is a negligible 0.50%, and availability has actually loosened sharply, climbing to 548% compared with a trough of 409% two weeks ago. That means there are more than five shares available to borrow for every one already borrowed, leaving plenty of room for new shorts to enter if sentiment reverses. The squeeze mechanics are not there.

Options positioning reinforces the call-heavy tilt described in the prior note, and if anything that skew has become more pronounced as the stock has recovered. The put/call ratio is running at 0.11, near the 52-week low of 0.10 and half a standard deviation above its 20-day mean. With a 52-week PCR high of 1.08, the current reading shows the market is not hedging this rally. Calls dominate the open interest by a wide margin, consistent with a trader base betting on a positive catalyst rather than bracing for disappointment.

The Street remains firmly constructive, though the consensus data is dated to mid-August. Wedbush and HC Wainwright reiterated their positive ratings in September, both holding price targets at $55. Piper Sandler lifted its target from $52 to $55 after the August results, and Jefferies initiated coverage in March at $55. That leaves the mean target at roughly $55.80, about 79% above the current price. The bull case rests on bezuclastinib advancing through three simultaneous FDA reviews, with the APEX trial posting a 54% objective response rate and 12-month overall survival of 87% in advanced systemic mastocytosis. The bear case is straightforward: a single-asset company whose entire valuation rests on clean regulatory outcomes, in a space where Sanofi's Ayvakit provides a credible competitive threat. The price-to-book multiple has moved up with the stock, now running at 13.7x on a 30-day basis, but negative earnings and EBITDA multiples reflect that this remains a pre-revenue clinical-stage business.

The most notable feature of the ownership register is Fairmount Funds Management, which holds a Schedule 13D activist position. Fairmount's last amendment disclosed a stake of 8.6%, trimmed from 9.9%, with the reduction coming via a $242.6 million sale at $34.66 in March and a further $127.4 million sale in January at $36.40. Both sales were above the current price, and Fairmount remains a top-five holder in the institutional data at 3.2% of shares. Their presence on the 13D register is worth watching, as any further amendment would be publicly filed. FMR (Fidelity) has become the dominant holder at 14.8% of shares, adding 2.6 million shares in the most recent quarter. BlackRock and T. Rowe Price also added meaningfully in the same period, and Wikipedia traffic for COGT has spiked to a z-score of 7.6 against its own 90-day history, indicating a sharp jump in retail attention that broadly tracks the price move this week.

Three of the last four earnings prints produced negative one-day moves, ranging from minus 2.7% to minus 8.7%, with five-day returns consistently worse in each case. The one outlier was a June print that gained 0.7% on the day and 6.1% over five days. With the November 2 print now 12 days out, the question for positioning is whether the week's covering and the rally into the event will be sustained, or whether the pattern of post-results selling reasserts itself.